Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer
Gastric Cancer · 2025-01 · 28 (1) · 83-95
DOI: 10.1007/s10120-024-01556-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 05.10.2024. Verfasst von Cecilie Riis Iden und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Stomach Neoplasms, Esophagogastric Junction, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kræftens Bekæmpelse, Dansk Kræftforsknings Fond, DCCC ctDNA Research Center - The Danish Research Center for Circulating Tumor DNA Guided Cancer Management.
Abstract (Originalsprache)
Background
Gastric and gastroesophageal junction (GEJ) cancer represents a significant global health challenge, with high recurrence rates and poor survival outcomes. This study investigates circulating tumor DNA (ctDNA) as a biomarker for assessing recurrence risk in patients with resectable gastric and GEJ adenocarcinomas (AC).
Methods
Patients with resectable gastric and GEJ AC, undergoing perioperative chemotherapy and surgery, were prospectively enrolled. Serial plasma samples were collected at baseline, after one cycle of chemotherapy, after preoperative chemotherapy, and after surgery. ctDNA was assessed by a ddPCR test (TriMeth), which targets the gastrointestinal cancer-specific methylation patterns of the genes C9orf50 , KCNQ5 , and CLIP4 . Results ctDNA analysis was performed on 229 plasma samples from 86 patients. At baseline, ctDNA was detected in 56% of patients, which decreased to 37% following one cycle of chemotherapy, 25% after preoperative chemotherapy and 15% after surgical resection. The presence of ctDNA after one cycle of chemotherapy was associated with reduced recurrence-free survival (RFS) (HR = 2.54, 95% confidence interval (CI) 1.33–4.85, p = 0.005) and overall survival (OS) (HR = 2.23, 95% CI 1.07–4.62, p = 0.032). Similarly, ctDNA after surgery was associated with significantly shorter RFS (HR = 6.22, 95% CI 2.39–16.2, p < 0.001) and OS (HR = 6.37, 95% CI 2.10–19.3, p = 0.001). Multivariable regression analysis confirmed ctDNA after surgery as an independent prognostic factor ( p < 0.001). Conclusion ctDNA analysis has the potential to identify patients at elevated risk of recurrence, thus providing personalized treatment strategies for patients with resectable gastric and GEJ cancer. Further validation in larger cohorts and ctDNA-guided interventions are needed for future clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
- Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus N, Denmark.
- Institute of Clinical Medicine, Faculty of Health, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark.
- Department of Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
- Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
- Department of Surgery & Transplantation, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
ORCID-Profile: Morten Mau-Sørensen
Förderung
- Kræftens Bekæmpelse
- Dansk Kræftforsknings Fond
- DCCC ctDNA Research Center - The Danish Research Center for Circulating Tumor DNA Guided Cancer Management
- Novo Nordisk Fonden
- Sygeforsikring Danmark
- DCCC ctDNA Research Center – The Danish Research Center for Circulating Tumor DNA Guided Cancer Management
- Jubilæumsfonden af 1986
- Klüwer Perssons scholarship
Zitieren
APA
Iden, C. R., Mustafa, S. M., Øgaard, N., Henriksen, T., Jensen, S. Ø., Ahlborn, L. B., Egebjerg, K., Baeksgaard, L., Garbyal, R. S., Nedergaard, M. K., Achiam, M. P., Andersen, C. L., & Mau-Sørensen, M. (2025). Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer, 28(1), 83-95. https://doi.org/10.1007/s10120-024-01556-9
Vancouver
Iden CR, Mustafa SM, Øgaard N, Henriksen T, Jensen SØ, Ahlborn LB, et al. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer. 2025;28(1):83-95. doi:10.1007/s10120-024-01556-9
BibTeX
@article{Iden2025,
author = {Iden, Cecilie Riis and Mustafa, Salah Mohammad and Øgaard, Nadia and Henriksen, Tenna and Jensen, Sarah Østrup and Ahlborn, Lise Barlebo and Egebjerg, Kristian and Baeksgaard, Lene and Garbyal, Rajendra Singh and Nedergaard, Mette Kjølhede and Achiam, Michael Patrick and Andersen, Claus Lindbjerg and Mau-Sørensen, Morten},
title = {Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer},
journal = {Gastric Cancer},
year = {2025},
volume = {28},
number = {1},
pages = {83--95},
doi = {10.1007/s10120-024-01556-9}
}
EUVIMED